Skip to main content
. 2018 Dec 3;13:8231–8245. doi: 10.2147/IJN.S174300

Figure 1.

Figure 1

CQ sensitized the ovarian cancer cells to chemotherapeutic drugs in vitro.

Notes: (A) Cell viability of A2780 cells was analyzed by MTT methods after treatment with gradient doses of CQ (5/10/20/50/100/200 µM) for 48 hours. (B) Cell viability of SKOV3 cells was analyzed by MTT methods after treatment with gradient doses of CQ (5/10/20/50/100/200 µM) for 48 hours. (C) Cell viability of A2780 cells was analyzed by MTT methods after treatment with gradient doses of DOX (0.0001/0.001/0.01/0.1/1 µM) pretreated with or without CQ (10 µM, 2 hours) for 48 hours. (D) Cell viability of SKOV3 cells was analyzed by MTT methods after treatment with gradient doses of DOX (0.0001/0.001/0.01/0.1/1 µM) pretreated with or without CQ (10 µM, 2 hours) for 48 hours. (E) Cell viability of A2780 and SKOV3 cells was analyzed by MTT methods after treatment with PTX (4 µM for A2780 and 40 nM for SKOV3 cells) pretreated with or without CQ (10 µM, 2 hours) for 48 hours. (F) Cell viability of A2780 and SKOV3 cells was analyzed by MTT methods after treatment with DDP (20 µM for both A2780 and SKOV3 cells) pretreated with or without CQ (10 µM, 2 hours) for 48 hours. (G) Cell viability of A2780/DOXR cells was analyzed by MTT methods after treatment with gradient doses of DOX (0.0001/0.001/0.01/0.1/1 µM) for 48 hours. (H) Using Western blot, we examined the expression of P-gp in wild-type and DOX-resistant A2780 cells. (I) Cell viability of A2780/DOXR cells was analyzed by MTT methods after treatment with gradient doses of DOX (0.0001/0.001/0.01/0.1/1 µM) pretreated with or without CQ (10 µM) for 48 hours. *P<0.05; **P<0.01; ***P<0.001.

Abbreviations: CQ, chloroquine; DOX, doxorubicin; ns, no significant difference; PTX, paclitaxel; ET, wild type.